Cancer Supportive Care Therapeutic Landscape Discussed by GBI Research in Its New Topical Report Available at MarketPublishers.com

13 Dec 2017 • by Natalie Aster

LONDON – Worldwide, biopharma research companies are developing a host of medicines in the cancer palliative care landscape. The size of the pipelines ranges from 24 medications in cancer anorexia/cachexia syndrome to 52 products to treat cancer related pain. Most products in cancer anorexia-cachexia syndrome target the growth hormone secretagogue receptor type 1 (ghrelin receptor or GHSR), though there are a set of other molecular targets in developmental stage.

Within the bone metastasis area, the most typical molecular targets are the tumour necrosis factor ligand superfamily member 11 (TNFSF11), and the hepatocyte growth factor (HGF) receptor, in tandem with a selection of others. Furthermore, within cancer pain, chemical messengers like the mu opioid receptor (MOP), and a set of ion channels, are the most prevailing type of target, mirroring the pain treatment scenario at large.

Topical research study “Cancer Supportive Care Drug Development Pipeline Review, 2017” drawn up by GBI Research drawn up by GBI Research gives an all-encompassing review and assessment of the cancer palliative care therapeutic landscape on a global scale.

The report is designed to give an all-round analysis of the therapeutic agents under development and the leading players engaged in developing drugs for cancer anorexia/cachexia syndrome, bony spread and cancer pain. It also provides insightful information on discontinued and dormant projects.

Reasons to Buy:

  • Get an understanding of the overall pipeline, with a capsule review of all products in therapeutic development for the 3 indication.
  • Evaluate the products at different stages of development, with an up-to-the-minute overview of each individual pipeline program in each of the indications, and an all-round picture of latest updates and milestones for each.
  • Obtain information on the companies, universities, etc. presently operating in the pipeline, and the products being introduced by them.
  • Understand the pipeline structure with respect to molecular target, molecule type, MoA and RoA.

A full collection of the publisher’s research studies is provided in GBI Research catalogue.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com